Deutsche Bank AG Buys Shares of 740,473 IQVIA Holdings Inc. $IQV

Key Points

• Deutsche Bank acquired 740,473 IQVIA shares worth approximately $143.1 million in the second quarter, giving it about a 0.45% stake. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in EPS versus the $3.03 consensus and $4.37 billion in revenue, up 8.7% year over year. The company also authorized a $2 billion share-repurchase program covering up to 6.8% of outstanding shares.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $241.88, although IQV shares opened at $249.62—near their 52-week high of $251.36. Insiders, meanwhile, sold 12,913 shares worth about $3.1 million over the past three months.

Deutsche Bank AG bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 740,473 shares of the medical research company's stock, valued at approximately $143,074,000. Deutsche Bank AG owned about 0.45% of IQVIA as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of IQV. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the fourth quarter worth about $28,000. Activest Wealth Management lifted its position in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock worth $31,000 after buying an additional 118 shares during the period. Finally, Financial Freedom LLC acquired a new stake in IQVIA in the 1st quarter worth about $25,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the business's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares of the company's stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company's stock.

IQVIA Stock Performance

Shares of IQV opened at $249.62 on Thursday. The business's 50 day moving average is $210.23 and its two-hundred day moving average is $186.82. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $251.36. The firm has a market cap of $41.09 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 2.04 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has approved a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Royal Bank Of Canada increased their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Robert W. Baird lifted their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. TD Cowen boosted their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley restated an "equal weight" rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source